tirzepatide patent expiry 2036 eli lilly Lilly's showed positive results in late-stage trial as treatment for heart failure Lilly's case against Mochi :
Description
SURPASS-2, a head-to-head trial against semaglutide 1mg, showed that Tirzepatide 5mg, 10mg, and 15mg produced greater HbA1c reductions (up to 2.6%) and weight loss (up to 12.4kg at 40 weeks) compared to semaglutide
Coverage varies by insurance plan
Regulates Sugar Levels : It helps your body lower blood sugar levels after eating by encouraging insulin production and reducing excess sugar release from your liver
Its designed for adults with obesity or overweight issues, aiming to enhance fullness from less food
